BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma: A Validation Study
Amber Louw(Edith Cowan University), Oluf Dimitri Røe(Norwegian University of Science and Technology), Johnni Hansen(Centre international de recherche sur le cancer), Mogens Vyberg(Aalborg University Hospital), Jenette Creaney(Asbestos Diseases Research Institute), Louise Andersen Lynggaard(Aalborg University Hospital), Christos Meristoudis(Aalborg University Hospital), Siaw Ming Chai(Universidad Peruana Cayetano Heredia), Ian M. Dick(The University of Western Australia), Tina Firth(The University of Western Australia), Gary Lee(Sir Charles Gairdner Hospital), Azadeh Birbaneh Asghari(Aalborg University Hospital), Vasiliki Panou(University of Southern Denmark), Chris Van Vliet(Queen Elizabeth II Medical Centre), Weronika Maria Szejniuk(Aalborg University Hospital)
Cited by 65
Related Papers
Integrative Molecular Characterization of Malignant Pleural Mesothelioma
|Cancer Discovery|2018|630
Conservative versus Interventional Treatment for Spontaneous Pneumothorax
|New England Journal of Medicine|2020|267
Painting, firefighting, and shiftwork
|Unknown|2010|257
Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma
|Journal of Clinical Oncology|2018|229